Federal contract award
75F40124P00440
CARDIOTOXICITY BIOMARKER ANALYSIS FOR PLASMA SAMPLES FROM CANCER PATIENTS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 621511 — Medical Laboratories |
| PSC | B504 — Chemical/Biological Studies and Analysis |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $99.4K |
| Current contract value | $99.4K |
| Potential contract value / ceiling | $99.4K |
| Start date | Sep 4, 2024 |
| Current end date | Sep 29, 2025 |
| Potential end date | Sep 29, 2025 |
| Latest award activity | Dec 6, 2024 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 6, 2024 | P00001 | $0 | CARDIOTOXICITY BIOMARKER ANALYSIS FOR PLASMA SAMPLES FROM CANCER PATIENTS |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Ryan Alexander | Contact | ryan.alexander@fda.hhs.gov | Source | Jun 21, 2024 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.